UY37707A - Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estos - Google Patents

Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estos

Info

Publication number
UY37707A
UY37707A UY0001037707A UY37707A UY37707A UY 37707 A UY37707 A UY 37707A UY 0001037707 A UY0001037707 A UY 0001037707A UY 37707 A UY37707 A UY 37707A UY 37707 A UY37707 A UY 37707A
Authority
UY
Uruguay
Prior art keywords
formulations
methods
human antibodies
rankl
rankl human
Prior art date
Application number
UY0001037707A
Other languages
English (en)
Inventor
Robert Brych Stephen
M Wong Lyanne
Jaymille Fallon
Michelle Goss Monica
Hua Gu Jian
K Ghattyvenkatakrishna Pavan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of UY37707A publication Critical patent/UY37707A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente se describen formulaciones farmacéuticas acuosas que comprenden denosumab u otro anticuerpo monoclonal anti-RANKL humano o parte de este, y características de pH, sistemas amortiguadores e inhibidores de agregación de aminoácidos. También se describe una presentación de la formulación para su uso, por ejemplo, en un recipiente de único uso, una jeringa de único uso, o un recipiente de vidrio, métodos de uso de las formulaciones y artículos para evitar o tratar enfermedades, y kits relacionados.
UY0001037707A 2017-04-28 2018-04-27 Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estos UY37707A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762492056P 2017-04-28 2017-04-28

Publications (1)

Publication Number Publication Date
UY37707A true UY37707A (es) 2018-10-31

Family

ID=62165668

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037707A UY37707A (es) 2017-04-28 2018-04-27 Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estos

Country Status (35)

Country Link
US (2) US11192952B2 (es)
EP (2) EP4190355B1 (es)
JP (3) JP7190822B2 (es)
KR (2) KR102681171B1 (es)
CN (1) CN110621342B (es)
AR (1) AR111497A1 (es)
AU (1) AU2018260750A1 (es)
BR (1) BR112019022188A2 (es)
CA (1) CA3054165A1 (es)
CL (3) CL2019003032A1 (es)
CO (1) CO2019011463A2 (es)
CR (1) CR20190538A (es)
DK (1) DK3615066T5 (es)
EA (1) EA201992570A1 (es)
ES (1) ES2973572T3 (es)
FI (1) FI3615066T3 (es)
HR (1) HRP20240167T1 (es)
HU (1) HUE065544T2 (es)
IL (2) IL293127B2 (es)
JO (1) JOP20190255A1 (es)
LT (1) LT3615066T (es)
MA (1) MA48462B1 (es)
MX (1) MX2023013460A (es)
MY (1) MY202479A (es)
PE (1) PE20200343A1 (es)
PH (1) PH12019502444A1 (es)
PL (1) PL3615066T3 (es)
PT (1) PT3615066T (es)
RS (1) RS65299B1 (es)
SG (1) SG11201909998TA (es)
SI (1) SI3615066T1 (es)
TN (2) TN2019000297A1 (es)
TW (1) TWI839331B (es)
UY (1) UY37707A (es)
WO (1) WO2018200918A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113365658A (zh) * 2018-11-16 2021-09-07 三星Bioepis股份有限公司 包含蛋白质的稳定的液体组合物
CN109374779A (zh) * 2018-12-17 2019-02-22 杭州奕安济世生物药业有限公司 一种蔗糖含量的快速检测方法
BR112021015034A2 (pt) 2019-02-18 2021-10-05 Eli Lilly And Company Formulação de anticorpo terapêutico
CN111704670B (zh) * 2020-08-18 2020-11-03 迈威(上海)生物科技股份有限公司 重组抗RANKL抗体IgG2型的二硫键异构体及其纯化方法
KR20240006586A (ko) * 2021-05-12 2024-01-15 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Rankl 및 ngf에 특이적으로 결합하는 항원 결합 분자, 및 이의 의학적 용도
IL310275A (en) 2021-08-12 2024-03-01 Amgen Inc Antibody formulations
WO2023092177A1 (en) * 2021-11-23 2023-06-01 Adalta Limited Rank-l binding molecules
WO2023179791A1 (en) * 2022-03-24 2023-09-28 Angitia Biomedicines Limited Treatment of musculoskeletal disorders
WO2024064878A1 (en) 2022-09-23 2024-03-28 The University Of North Carolina At Chapel Hill Methods and compositions for the treatment of melanoma
WO2024104409A1 (zh) * 2022-11-16 2024-05-23 苏州盛迪亚生物医药有限公司 一种含抗rankl-ngf双特异性抗体的药物组合物
WO2024184280A1 (en) * 2023-03-03 2024-09-12 Alvotech Hf Denosumab formulation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU103003A (sh) 2001-06-26 2006-05-25 Abgenix Inc. Antitela za opgl
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
CA2672902C (en) 2006-12-21 2012-11-27 Amgen Inc. Formulations
US7951368B2 (en) * 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
AU2009210741A1 (en) * 2008-02-07 2009-08-13 Amgen Inc. Stabilized protein compositions
CL2009001735A1 (es) 2008-08-19 2010-02-19 Regeneron Pharma Anticuerpo humano o fragmento de union a antigeno del mismo que une e inhibe actividad de ligando del activador del receptor de nf-kb (rankl); adn codificante; vector de expresion; metodo para producir dicho anticuerpo; composicion farmaceutica que lo comprende; uso para atenuar o inhibir enfermedad o condicion mediada por rankl
US9265834B2 (en) * 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
WO2011141926A2 (en) 2010-05-10 2011-11-17 Intas Biopharmaceuticals Limited Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
EP2433644A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer therapeutics
CA2832560A1 (en) * 2011-04-07 2012-10-18 Glaxosmithkline Llc Formulations with reduced viscosity
KR101759694B1 (ko) 2011-10-28 2017-07-19 인테그리티 바이오, 아이엔씨. 아미노산을 함유하는 단백질 제제
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
CN103965357B (zh) 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
WO2015134406A1 (en) * 2014-03-03 2015-09-11 La Jolla Biologics, Inc. Stable aqueous recombinant protein formulations
CN106659785B (zh) 2014-05-07 2021-04-30 武田有限公司 包含gm-csf中和化合物的液体制剂

Also Published As

Publication number Publication date
CO2019011463A2 (es) 2019-10-31
HRP20240167T1 (hr) 2024-04-26
IL268704B (en) 2022-06-01
CL2023002505A1 (es) 2024-03-08
AU2018260750A1 (en) 2019-08-29
TWI839331B (zh) 2024-04-21
IL293127B1 (en) 2024-02-01
EP4190355A1 (en) 2023-06-07
JOP20190255A1 (ar) 2019-10-27
RS65299B1 (sr) 2024-04-30
KR20190140464A (ko) 2019-12-19
PT3615066T (pt) 2024-03-08
AR111497A1 (es) 2019-07-17
LT3615066T (lt) 2024-02-26
SI3615066T1 (sl) 2024-04-30
EA201992570A1 (ru) 2020-03-20
CL2019003032A1 (es) 2020-02-21
TN2021000055A1 (en) 2022-10-03
FI3615066T3 (fi) 2024-02-29
ES2973572T3 (es) 2024-06-20
CN110621342B (zh) 2024-08-02
JP2018188430A (ja) 2018-11-29
CL2020002012A1 (es) 2020-10-16
US11192952B2 (en) 2021-12-07
TW201841654A (zh) 2018-12-01
JP7190822B2 (ja) 2022-12-16
JP2023166396A (ja) 2023-11-21
JP7356525B2 (ja) 2023-10-04
DK3615066T3 (da) 2024-03-11
WO2018200918A1 (en) 2018-11-01
MA48462B1 (fr) 2024-05-31
EP4190355B1 (en) 2024-09-25
CR20190538A (es) 2020-02-26
PH12019502444A1 (en) 2020-07-20
IL268704A (en) 2019-10-31
US20220143181A1 (en) 2022-05-12
US20200354463A1 (en) 2020-11-12
HUE065544T2 (hu) 2024-05-28
MY202479A (en) 2024-04-30
MX2023013460A (es) 2023-12-15
EP3615066B1 (en) 2023-12-27
KR20240110083A (ko) 2024-07-12
PL3615066T3 (pl) 2024-04-29
KR102681171B1 (ko) 2024-07-05
EP3615066A1 (en) 2020-03-04
MA48462A (fr) 2020-03-04
WO2018200918A8 (en) 2019-10-17
CA3054165A1 (en) 2018-11-01
US11873343B2 (en) 2024-01-16
CN110621342A (zh) 2019-12-27
TN2019000297A1 (en) 2021-05-07
BR112019022188A2 (pt) 2020-05-12
IL293127B2 (en) 2024-06-01
IL293127A (en) 2022-07-01
DK3615066T5 (da) 2024-09-02
JP2022062059A (ja) 2022-04-19
SG11201909998TA (en) 2019-11-28
PE20200343A1 (es) 2020-02-14

Similar Documents

Publication Publication Date Title
UY37707A (es) Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estos
CY1123657T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
BR112015022210A2 (pt) formulações farmacêuticas aquosas estáveis, seu uso, artigo de manufatura, métodos de redução da agregação de um anticorpo monoclonal terapêutico e método de produção de uma formulação farmacêutica.
CL2020001974A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093)
CO2019011021A2 (es) Formulacion estable de anticuerpos
MX2019010282A (es) Formulacion de anticuerpos monoclonales.
BR112017027778A2 (pt) anticorpos para o fator xi e métodos de uso
CR20190400A (es) Formulaciones de anticuerpo monoclonal anti-vrs
EA202091318A1 (ru) Препарат, содержащий аденовирус группы b
MX2021009851A (es) Formulacion de anticuerpos terapeuticos.
BR112021019612A2 (pt) Formulações, recipiente, artigo de fabricação, método para produzir a formulação e método para inibir a agregação de uma proteína presente em uma solução aquosa
CO2020013571A2 (es) Formulaciones estables de anticuerpos terapéuticos
AR117607A1 (es) Formulaciones de anticuerpo líquidas de alta concentración
PE20210779A1 (es) NUEVA FORMULACIOìN ESTABLE DE ALTA CONCENTRACIOìN PARA ANTICUERPOS ANTI-FXIa
CO2022005737A2 (es) Formulación estable de anticuerpo de integrina
CL2022001243A1 (es) Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas divisional solicitud no. 201903032
CR20200552A (es) Fórmula de suspención de alta concentración para medicamentos en cápsula de gel blanda paae resfriado y gripe
CO2020013545A2 (es) Formulación estable de anticuerpos
EA202191990A1 (ru) Состав терапевтического антитела
UA118310U (uk) Готовий лікарський засіб для застосування при захворюваннях печінки
AR096455A1 (es) Vacuna para la malaria